explore -WSS

explore

author：explore 2025-09-27 04:26:08 - browse：9898

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Will.i.am, Britney Spears release new single, 'Mind Your Business'

WSS

Medicare solvency divides Republicans at the presidential debate

Organ transplantation is at a crossroads. Major reform is needed

Why an extreme heat and wildfire smoke combination can be so dangerous

UCSF medical school apologizes for unethical prisoner experiments

White House launches permanent pandemic office

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

hotspot

explore

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

White House calls on federal agencies to crack down on AI abuses

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

MoonLake credibility takes another hit with mid

As demand for Covid shots wanes, Moderna seeks its next success

10 million people disenrolled from Medicaid over past six months

Sports medicine is finally prioritizing gender equality

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Novavax promises a turnaround & Lilly roils the obesity market

FDA approves Recor Medical high blood pressure device

focus

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

CDC backtracks, saying fully vaccinated people can go maskless indoors

A clever new way to fix Medicaid and graduate medical education

The new shift in health care is toward less care

Extreme heat events are a public health emergency

Biotech incubator Curie.Bio graduates its first startup

leisure time

explore

knowledge

focus